Expanding Treatment Options for Recurrent/Metastatic SCCHN
Release date 22-10-2020
Expiration date 22-10-2021
Standard-of-care treatments for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) are rapidly expanding. View expert faculty presentations and downloadable slides from the recent SCCHN live webinar, Expanding Treatment Options for Recurrent/Metastatic SCCHN, which includes discussion of the latest evidence-based treatment recommendations and emerging treatment strategies.
Ye Guo, MD | Chair & Moderator
Department of Medical Oncology
Shanghai East Hospital Tongji
University School of Medicine
Ye Guo, MD, is the Deputy Director of the Oncology Department at Tongji University East Hospital in Shanghai, China. His research focuses on new drug development, and he serves as Director of the Phase I Trial Unit at Tongji University, Shanghai East Hospital. Previously, Dr. Guo led the research team for head and neck (H&N) cancer and lymphoma at Fudan University Shanghai Cancer Center where he has been Deputy Director of the Medical Oncology Department since 2010. He is the Deputy Secretary-General of the Chinese Society of Clinical Oncology (CSCO), Chairman of the H&N Cancer Committee (CSCO), member of the Standing Committee of the Union of Chinese Lymphoma Investigators (UCLI), Vice Chairman of the H&N Cancer Committee and Secretary-General of the Lymphoma Committee of Shanghai Anti-Cancer Association. Dr. Guo is a principal investigator for multiple key clinical trials of H&N cancer in China, and has published numerous articles in international, peer-reviewed journals.
Kunyu Yang, MD, PhD
Cancer Center, Union Hospital
Tongji Medical College Huazhong
University of Science and Technology
Kunyu Yang, MD, PhD is Professor and Chief of the Department of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. He received his Bachelor in Medicine from Wannan Medical College (Wuhu, 1994), his Master in Medicine from Tongij Medical Huazhong University of Science and Technology (Wuhan, 1997), and his doctoral degree from the Department of Radiation Oncology in Saarland University Hospital (Germany, 2004). Professor Yang is involved in clinical and translational research of head and neck cancer and received several research grants evaluating novel treatment modalities and radioresistance of nasopharyngeal cancer. He is author and co-author of many research articles published in peer reviewed journals.
Ana Castro, MD, PhD
Lenitudes Medical Center & Research
Santa Maria da Feira, Portugal
Ana Ferreira Castro, MD, PhD is a medical oncologist and currently serves as Clinical Director of Lenitudes Medical Center & Research in Santa Maria da Feira, Portugal. She has been President of the Portuguese Head and Neck Cancer Study Group since 2014, and an oncology representative on the Board of the European Organization for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group. Dr. Castro has been Medical Oncology Officer for the European Head and Neck Society (EHNS) since April 2018. She is also a member of the Portuguese Oncology Society (SPO) and European Society of Medical Oncology (ESMO), and a member of ESMO Congress’ Scientific Committee in 2016, 2018, 2020 and 2021. She is involved in multiple head and neck cancer clinical trials as principal investigator or sub-investigator and is author and co-author of many scientific papers published in indexed journals. Additionally, Dr. Castro serves as invited assistant of the Abel Salazar Biomedical Sciences Institute (ICBAS) as professor of Medicine for 5th grade medical students and has been a promoter of several Masters of Science (MSc) in Medicine since 2015.
- First-line treatment options for R/M SCCHN: Evaluating the evidence and recommendations in China | Ye Guo, MD, PhD
Progression after platinum-based therapy: Considering treatment options | Kunyu Yang, MD, PhD
Future management of R/M SCCHN: What do we want to know? | Ana Castro, MD, PhD
This educational activity is designed for medical oncologists, radiation oncologists, otolaryngologists, and other healthcare professionals involved or interested in the management of patients with head and neck cancer.
Upon completion of this educational activity, participants should be able to:
- Assess evidence-based first-line treatment options for patients with recurrent/metastatic (R/M) SCCHN, and discuss guideline recommendations in China
- Evaluate treatment strategies after progression on platinum-based therapy
- Identify factors that impact treatment selection in R/M SCCHN, and describe ongoing research strategies
Provided by ACE Oncology.
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
This on-demand webcast includes content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve knowledge, competence, and performance of clinicians in order to improve patient care.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Ye Guo has served as an advisor or consultant for Merck Serono, Boehringer Ingelheim, BMS,and MSD. He has served as a speaker or a member of a speakers bureau for Merck Serono, Roche, Celgene, Janssen, Bayer, BMS, and MSD. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Kunyu Yang has served as an advisor or consultant for Merck KGaA. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Ana Castro has served as an advisor or consultant for Merck, MSD, and BMS. She has served as a speaker or a member of a speakers bureau for Merck, MSD, and BMS. Prof Castro received grants for clinical research from Merck. Any unlabeled/unapproved uses of drugs or products referenced in her presentation will be specified.
The employees of ACE Oncology have disclosed no relevant financial relationships.
ACE Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.